

# Veli-Pekka Harjola

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/167873/publications.pdf>

Version: 2024-02-01

100  
papers

7,695  
citations

81900

39  
h-index

53230

85  
g-index

104  
all docs

104  
docs citations

104  
times ranked

7606  
citing authors

#	ARTICLE	IF	CITATIONS
1	The emergency department arrival mode and its relations to ED management and 30-day mortality in acute heart failure: an ancillary analysis from the EURODEM study. <i>BMC Emergency Medicine</i> , 2022, 22, 27.	1.9	0
2	Low body temperature and mortality in older patients with frailty in the emergency department. <i>Aging Clinical and Experimental Research</i> , 2022, 34, 1453-1457.	2.9	3
3	Performance of Early Capillary Refill Time Measurement on Outcomes in Cardiogenic Shock: An Observational, Prospective Multicentric Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 1230-1238.	5.6	17
4	Epidemiology, treatment and outcome of patients with lower respiratory tract infection presenting to emergency departments with dyspnoea ( AANZDEM and EuroDEM studies). <i>EMA - Emergency Medicine Australasia</i> , 2021, 33, 58-66.	1.1	0
5	Kinetics of procalcitonin, C-reactive protein and interleukin-6 in cardiogenic shock – Insights from the CardShock study. <i>International Journal of Cardiology</i> , 2021, 322, 191-196.	1.7	13
6	Survival and quality of life after early discharge in low-risk pulmonary embolism. <i>European Respiratory Journal</i> , 2021, 57, 2002368.	6.7	17
7	Mortality risk prediction in elderly patients with cardiogenic shock: results from the CardShock study. <i>ESC Heart Failure</i> , 2021, 8, 1398-1407.	3.1	13
8	Predictive value of plasma proenkephalin and neutrophil gelatinase-associated lipocalin in acute kidney injury and mortality in cardiogenic shock. <i>Annals of Intensive Care</i> , 2021, 11, 25.	4.6	13
9	Soluble triggering receptor expressed on myeloid cells-1 is a marker of organ injuries in cardiogenic shock: results from the CardShock Study. <i>Clinical Research in Cardiology</i> , 2021, , 1.	3.3	5
10	Reply to: High levels of plasma biomarkers at 24h were found to be strong predictors of 90-day mortality: beware of some potential confounders!. <i>Annals of Intensive Care</i> , 2021, 11, 46.	4.6	0
11	Venous lactate improves the prediction of in-hospital adverse outcomes in normotensive pulmonary embolism. <i>European Journal of Internal Medicine</i> , 2021, 86, 25-31.	2.2	15
12	Outcome of patients with different clinical presentations of high-risk pulmonary embolism. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 787-796.	1.0	11
13	Systematic geriatric assessment for older patients with frailty in the emergency department: a randomised controlled trial. <i>BMC Geriatrics</i> , 2021, 21, 408.	2.7	8
14	Effect of Inhaled Xenon on Cardiac Function in Comatose Survivors of Out-of-Hospital Cardiac Arrest – A Substudy of the Xenon in Combination With Hypothermia After Cardiac Arrest Trial. , 2021, 3, e0502.		4
15	External validation and comparison of the CardShock and IABP-SHOCK II risk scores in real-world cardiogenic shock patients. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 16-24.	1.0	24
16	Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. <i>European Heart Journal</i> , 2020, 41, 509-518.	2.2	106
17	Current Use and Impact on 30-Day Mortality of Pulmonary Artery Catheter in Cardiogenic Shock Patients: Results From the CardShock Study. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 1426-1433.	2.8	39
18	Get with the guidelines: management of chronic obstructive pulmonary disease in emergency departments in Europe and Australasia is sub-optimal. <i>Internal Medicine Journal</i> , 2020, 50, 200-208.	0.8	10

#	ARTICLE	IF	CITATIONS
19	Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics. <i>European Journal of Heart Failure</i> , 2020, 22, 290-299.	7.1	55
20	Pre-hospital management protocols and perceived difficulty in diagnosing acute heart failure. <i>ESC Heart Failure</i> , 2020, 7, 290-297.	3.1	7
21	Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 181-195.	7.1	47
22	National Early Warning Score 2 (NEWS2) and 3-level triage scale as risk predictors in frail older adults in the emergency department. <i>BMC Emergency Medicine</i> , 2020, 20, 83.	1.9	13
23	Association of miR-21-5p, miR-122-5p, and miR-320a-3p with 90-Day Mortality in Cardiogenic Shock. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7925.	4.1	11
24	Epidemiology, pathophysiology and contemporary management of cardiogenic shock—A position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1315-1341.	7.1	244
25	Prognostic impact of angiographic findings, procedural success, and timing of percutaneous coronary intervention in cardiogenic shock. <i>ESC Heart Failure</i> , 2020, 7, 768-773.	3.1	4
26	Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 4-22.	1.9	49
27	CTGFBP4 as a novel prognostic biomarker in acute heart failure. <i>ESC Heart Failure</i> , 2020, 7, 434-444.	3.1	14
28	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1298-1314.	7.1	50
29	Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use. <i>Cardiac Failure Review</i> , 2020, 6, e19.	3.0	37
30	Seasonal variations of patients presenting dyspnea to emergency departments in Europe: Results from the EURODEM Study. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 1879-1886.	0.9	3
31	Levels of Growth Differentiation Factor 15 and Early Mortality Risk Stratification in Cardiogenic Shock. <i>Journal of Cardiac Failure</i> , 2019, 25, 894-901.	1.7	6
32	Short-Term Therapies for Treatment of Acute and Advanced Heart Failure—Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?. <i>Journal of Clinical Medicine</i> , 2019, 8, 1834.	2.4	14
33	A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. <i>International Journal of Cardiology</i> , 2019, 297, 83-90.	1.7	42
34	Protein-based cardiogenic shock patient classifier. <i>European Heart Journal</i> , 2019, 40, 2684-2694.	2.2	30
35	Acute heart failure congestion and perfusion status—Impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1338-1352.	7.1	170
36	Hypoalbuminemia is a frequent marker of increased mortality in cardiogenic shock. <i>PLoS ONE</i> , 2019, 14, e0217006.	2.5	31

#	ARTICLE	IF	CITATIONS
37	Treatment and outcome of adult patients with acute asthma in emergency departments in Australasia, South East Asia and Europe: Are guidelines followed? AANZDEM/EuroDEM study. <i>EMA - Emergency Medicine Australasia</i> , 2019, 31, 756-762.	1.1	4
38	Pulmonary embolism location is associated with the co-existence of the deep venous thrombosis. <i>Blood Coagulation and Fibrinolysis</i> , 2019, 30, 188-192.	1.0	4
39	Epidemiology of patients presenting with dyspnea to emergency departments in Europe and the Asia-Pacific region. <i>European Journal of Emergency Medicine</i> , 2019, 26, 345-349.	1.1	48
40	Prognostic impact of baseline and residual SYNTAX scores in cardiogenic shock. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1-8.	1.7	11
41	The use of diuretics in heart failure with congestion â€” a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 137-155.	7.1	605
42	Circulating MiRNA Dynamics in ST-Segment Elevation Myocardial Infarction-driven Cardiogenic Shock. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2019, 72, 783-786.	0.6	3
43	Circulating levels of <scp>microRNA</scp> 423â€”5p are associated with 90-day mortality in cardiogenic shock. <i>ESC Heart Failure</i> , 2019, 6, 98-102.	3.1	15
44	Treatments targeting inotropy. <i>European Heart Journal</i> , 2019, 40, 3626-3644.	2.2	123
45	Comparative Analysis of Short-Term Outcomes of Patients With Heart Failure With a Mid-Range Ejection Fraction After Acute Decompensation. <i>American Journal of Cardiology</i> , 2019, 123, 84-92.	1.6	12
46	Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan. <i>Cardiac Failure Review</i> , 2019, 5, 155-161.	3.0	13
47	Prevalence, Temporal Evolution, and Impact on Survival of Ventricular Conduction Blocks in Patients With Acute Coronary Syndrome and Cardiogenic Shock. <i>American Journal of Cardiology</i> , 2018, 122, 199-205.	1.6	5
48	Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 75-81.	3.0	9
49	Indications and practical approach to non-invasive ventilation in acute heart failure. <i>European Heart Journal</i> , 2018, 39, 17-25.	2.2	111
50	Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2018, 20, 1081-1099.	7.1	57
51	Short-term outcomes of heart failure patients with reduced and preserved ejection fraction after acute decompensation according to the final destination after emergency department care. <i>Clinical Research in Cardiology</i> , 2018, 107, 698-710.	3.3	14
52	Altered mental status predicts mortality in cardiogenic shock â€” results from the CardShock study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 38-44.	1.0	26
53	Assessment of early treatment response by rapid cardiothoracic ultrasound in acute heart failure: Cardiac filling pressures, pulmonary congestion and mortality. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 311-320.	1.0	29
54	The BRONCHâ€”AHF study: effects on short-term outcome of nebulized bronchodilators in emergency department patients diagnosed with acute heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 822-826.	7.1	4

#	ARTICLE	IF	CITATIONS
55	Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 16-37.	7.1	239
56	Association between hypo- and hyperkalemia and outcome in acute heart failure patients: the role of medications. <i>Clinical Research in Cardiology</i> , 2018, 107, 214-221.	3.3	28
57	Focused echocardiography and lung ultrasound protocol for guiding treatment in acute heart failure. <i>ESC Heart Failure</i> , 2018, 5, 120-128.	3.1	63
58	Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-term Registry. <i>European Journal of Heart Failure</i> , 2018, 20, 332-341.	7.1	69
59	Acute kidney injury in cardiogenic shock: definitions, incidence, haemodynamic alterations, and mortality. <i>European Journal of Heart Failure</i> , 2018, 20, 572-581.	7.1	68
60	Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity score matched study. <i>European Journal of Heart Failure</i> , 2018, 20, 345-354.	7.1	92
61	Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 3-15.	7.1	157
62	Comparison of the use of comprehensive point-of-care test panel to conventional laboratory process in emergency department. <i>BMC Emergency Medicine</i> , 2018, 18, 43.	1.9	15
63	Use of levosimendan in acute heart failure. <i>European Heart Journal Supplements</i> , 2018, 20, I2-I10.	0.1	27
64	Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. <i>Intensive Care Medicine</i> , 2018, 44, 847-856.	8.2	106
65	Management of cardiogenic shock complicating myocardial infarction. <i>Intensive Care Medicine</i> , 2018, 44, 760-773.	8.2	126
66	Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 173-182.	2.8	282
67	Predictive value of the baseline electrocardiogram ST segment pattern in cardiogenic shock: Results from the CardShock Study. <i>Annals of Noninvasive Electrocardiology</i> , 2018, 23, e12561.	1.1	6
68	Editor's Choice-The role of the emergency department in the management of acute heart failure: An international perspective on education and research. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2017, 6, 421-429.	1.0	28
69	Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock. <i>Annals of Intensive Care</i> , 2017, 7, 6.	4.6	58
70	The impact of emergency medical services in acute heart failure. <i>International Journal of Cardiology</i> , 2017, 232, 222-226.	1.7	8
71	The role of pre-hospital management in acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 287-289.	7.1	6
72	Risk Stratification for Patients in Cardiogenic Shock After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1913-1920.	2.8	269

#	ARTICLE	IF	CITATIONS
73	Morphine Use in the ED and Outcomes of Patients With Acute Heart Failure. <i>Chest</i> , 2017, 152, 821-832.	0.8	45
74	Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1242-1254.	7.1	339
75	Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2017, 19, 821-836.	7.1	252
76	Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1574-1585.	7.1	568
77	Triage quality control is missing tools—a new observation technique for ED quality improvement. <i>International Journal for Quality in Health Care</i> , 2017, 29, 295-300.	1.8	5
78	IMPROV-ED study: outcomes after discharge for an episode of acute-decompensated heart failure and comparison between patients discharged from the emergency department and hospital wards. <i>Clinical Research in Cardiology</i> , 2017, 106, 369-378.	3.3	17
79	Use of noninvasive and invasive mechanical ventilation in cardiogenic shock: A prospective multicenter study. <i>International Journal of Cardiology</i> , 2017, 230, 191-197.	1.7	33
80	Frequency and Prognostic Significance of Abnormal Liver Function Tests in Patients With Cardiogenic Shock. <i>American Journal of Cardiology</i> , 2017, 120, 1090-1097.	1.6	17
81	Inhaled Xenon Attenuates Myocardial Damage in Comatose Survivors of Out-of-Hospital Cardiac Arrest. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2652-2660.	2.8	30
82	Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	20
83	The association of admission blood glucose level with the clinical picture and prognosis in cardiogenic shock—Results from the CardShock Study. <i>International Journal of Cardiology</i> , 2017, 226, 48-52.	1.7	38
84	Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality. <i>Critical Care</i> , 2016, 20, 208.	5.8	145
85	The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion. <i>International Journal of Cardiology</i> , 2016, 218, 150-157.	1.7	60
86	Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients. <i>International Journal of Cardiology</i> , 2016, 215, 26-31.	1.7	12
87	Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. <i>International Journal of Cardiology</i> , 2016, 222, 303-312.	1.7	103
88	Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016, 18, 226-241.	7.1	455
89	Effect of Inhaled Xenon on Cerebral White Matter Damage in Comatose Survivors of Out-of-Hospital Cardiac Arrest. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1120.	7.4	97
90	N-terminal Pro-brain Natriuretic Peptide, High-sensitivity Troponin and Pulmonary Artery Clot Score as Predictors of Right Ventricular Dysfunction in Echocardiography. <i>Heart Lung and Circulation</i> , 2016, 25, 592-599.	0.4	9

#	ARTICLE	IF	CITATIONS
91	Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. <i>European Journal of Heart Failure</i> , 2015, 17, 544-558.	7.1	315
92	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine – short version. <i>European Heart Journal</i> , 2015, 36, 1958-1966.	2.2	105
93	Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy. <i>Clinical Chemistry</i> , 2015, 61, 368-378.	3.2	37
94	Clinical picture and risk prediction of short-term mortality in cardiogenic shock. <i>European Journal of Heart Failure</i> , 2015, 17, 501-509.	7.1	520
95	Acute Heart Failure With and Without Concomitant Acute Coronary Syndromes: Patient Characteristics, Management, and Survival. <i>Journal of Cardiac Failure</i> , 2014, 20, 723-730.	1.7	29
96	Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1541-1550.	2.8	84
97	Body Mass Index and Mortality in Acutely Decompensated Heart Failure Across the World. <i>Journal of the American College of Cardiology</i> , 2014, 63, 778-785.	2.8	213
98	Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 239-248.	7.1	214
99	The effect of moderate exercise training on skeletal muscle myosin heavy chain distribution in chronic heart failure. <i>International Journal of Cardiology</i> , 2006, 109, 335-338.	1.7	10
100	A Clinical Study of Beta-Haemolytic Groups A, B, C and G Streptococcal Bacteremia in Adults over an 8-Year Period. <i>Scandinavian Journal of Infectious Diseases</i> , 1997, 29, 233-238.	1.5	25